PerkinElmer, Inc. (NYSE:PKI) Director Peter Barrett sold 7,071 shares of the business’s stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $71.07, for a total value of $502,535.97. Following the sale, the director now directly owns 26,271 shares of the company’s stock, valued at $1,867,079.97. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

PerkinElmer, Inc. (NYSE PKI) traded up $0.34 during midday trading on Wednesday, reaching $71.61. The company had a trading volume of 671,500 shares, compared to its average volume of 633,822. PerkinElmer, Inc. has a twelve month low of $49.72 and a twelve month high of $73.05. The company has a current ratio of 2.59, a quick ratio of 2.09 and a debt-to-equity ratio of 0.44. The company has a market cap of $7,890.00, a PE ratio of 25.64, a price-to-earnings-growth ratio of 2.01 and a beta of 0.77.

The firm also recently announced a quarterly dividend, which will be paid on Friday, February 9th. Investors of record on Friday, January 19th will be paid a dividend of $0.07 per share. The ex-dividend date of this dividend is Thursday, January 18th. This represents a $0.28 dividend on an annualized basis and a yield of 0.39%. PerkinElmer’s payout ratio is 12.67%.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/11/15/perkinelmer-inc-pki-director-peter-barrett-sells-7071-shares-of-stock.html.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. increased its stake in PerkinElmer by 2.6% during the 2nd quarter. Vanguard Group Inc. now owns 10,886,642 shares of the medical research company’s stock worth $741,816,000 after purchasing an additional 273,975 shares in the last quarter. Janus Henderson Group PLC bought a new stake in PerkinElmer during the 2nd quarter worth approximately $436,483,000. BlackRock Inc. increased its stake in PerkinElmer by 2.4% during the 2nd quarter. BlackRock Inc. now owns 5,929,277 shares of the medical research company’s stock worth $404,022,000 after purchasing an additional 141,650 shares in the last quarter. Pictet Asset Management Ltd. increased its stake in PerkinElmer by 2.1% during the 2nd quarter. Pictet Asset Management Ltd. now owns 3,433,659 shares of the medical research company’s stock worth $216,526,000 after purchasing an additional 71,540 shares in the last quarter. Finally, King Luther Capital Management Corp increased its stake in PerkinElmer by 1.3% during the 3rd quarter. King Luther Capital Management Corp now owns 2,562,833 shares of the medical research company’s stock worth $176,759,000 after purchasing an additional 32,248 shares in the last quarter. 91.54% of the stock is owned by institutional investors and hedge funds.

PKI has been the subject of several recent research reports. Zacks Investment Research raised PerkinElmer from a “hold” rating to a “buy” rating and set a $78.00 price objective for the company in a report on Wednesday, July 19th. Citigroup Inc. reissued a “buy” rating and set a $80.00 price objective (up from $74.00) on shares of PerkinElmer in a report on Tuesday, September 26th. Piper Jaffray Companies reissued a “buy” rating and set a $81.00 price objective on shares of PerkinElmer in a report on Friday, August 4th. Robert W. Baird reissued a “buy” rating and set a $72.00 price objective on shares of PerkinElmer in a report on Friday, October 20th. Finally, Jefferies Group LLC reissued a “hold” rating and set a $70.00 price objective on shares of PerkinElmer in a report on Friday, October 20th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and six have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $68.64.

PerkinElmer Company Profile

PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.

Insider Buying and Selling by Quarter for PerkinElmer (NYSE:PKI)

Receive News & Stock Ratings for PerkinElmer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer Inc. and related stocks with our FREE daily email newsletter.